Human-Specific Bacterial Pore-Forming Toxins Induce Programmed Necrosis in Erythrocytes

Timothy J. LaRocca,a Elizabeth A. Stivison,b Eldad A. Hod,c Steven L. Spitalnik,c Peter J. Cowan,d Tara M. Randis,a Adam J. Ratnera

Department of Pediatrics,a Institute of Human Nutrition,b and Department of Pathology and Cell Biology,c Columbia University, New York, New York, USA; Immunology Research Center, St. Vincent’s Hospital, Melbourne, Australiad

ABSTRACT A subgroup of the cholesterol-dependent cytolysin (CDC) family of pore-forming toxins (PFTs) has an unusually narrow host range due to a requirement for binding to human CD59 (hCD59), a glycosylphosphatidylinositol (GPI)-linked complement regulatory molecule. hCD59-specific CDCs are produced by several organisms that inhabit human mucosal surfaces and can act as pathogens, including Gardnerella vaginalis and Streptococcus intermedius. The consequences and potential selective advantages of such PFT host limitation have remained unknown. Here, we demonstrate that, in addition to species restriction, PFT ligation of hCD59 triggers a previously unrecognized pathway for programmed necrosis in primary erythrocytes (red blood cells [RBCs]) from humans and transgenic mice expressing hCD59. Because they lack nuclei and mitochondria, RBCs have typically been thought to possess limited capacity to undergo programmed cell death. RBC programmed necrosis shares key molecular factors with nucleated cell necroptosis, including dependence on Fas/FasL signaling and RIP1 phosphorylation, necrosome assembly, and restriction by caspase-8. Death due to programmed necrosis in RBCs is executed by acid sphingomyelinase-dependent ceramide formation, NADPH oxidase- and iron-dependent reactive oxygen species formation, and glycolytic formation of advanced glycation end products. Bacterial PFTs that are hCD59 independent do not induce RBC programmed necrosis. RBC programmed necrosis is biochemically distinct from apoptosis, the only other known programmed cell death pathway in mature RBCs. Importantly, RBC programmed necrosis enhances the growth of PFT-producing pathogens during exposure to primary RBCs, consistent with a role for such signaling in microbial growth and pathogenesis.

IMPORTANCE In this work, we provide the first description of a new form of programmed cell death in erythrocytes (RBCs) that occurs as a consequence of cellular attack by human-specific bacterial toxins. By defining a new RBC death pathway that shares important components with necroptosis, a programmed necrosis module that occurs in nucleated cells, these findings expand our understanding of RBC biology and RBC-pathogen interactions. In addition, our work provides a link between cholesterol-dependent cytolysin (CDC) host restriction and promotion of bacterial growth in the presence of RBCs, which may provide a selective advantage to human-associated bacterial strains that elaborate such toxins and a potential explanation for the narrowing of host range observed in this toxin family.

Erythrocytes (red blood cells [RBCs]) are circulating, terminally differentiated cells that transport O2 and CO2 in all mammals, including humans. Mature human RBCs circulate for ~120 days and are cleared by several distinct mechanisms (1). Genetic, inflammatory, or immune-mediated processes (e.g., sickle cell disease, hereditary spherocytosis, and cold agglutinin disease) can shorten the RBC life span, producing anemia with serious clinical consequences (2, 3). Due to their lack of nuclei and mitochondria and their inability to synthesize proteins, mature RBCs were thought to be incapable of sophisticated cellular processes such as programmed cell death (PCD). Recently, apoptosis, a Ca2+-dependent PCD unique to RBCs, was proposed to serve as an apoptosis-like process for triggering RBC clearance by macrophages (4). Thus, there is an expanding appreciation for the potential role of PCD in RBC biology and in the pathophysiology of anemia in various settings, including heart failure, sickle cell disease, and malaria (4).

Pore-forming toxins (PFTs) are bacterial virulence factors that bind host cell receptors, oligomerize, and insert a functional pore into the membrane that may induce osmotic lysis (5). Pore formation triggers target cell signaling pathways, including proinflammatory, membrane repair, and PCD modules (5). The cholesterol-dependent cytolysins (CDCs) constitute a PFT subfamily that relies on cholesterol binding (6). Most CDC monomers bind directly to cholesterol, but a subset requires ligation of human CD59 (hCD59), a glycosylphosphatidylinositol (GPI)-anchored complement regulatory molecule, thereby restricting their host range (6–8). PFTs induce RBC death and are thus termed hemolytic; however, this hemolytic ability is often used solely as a measure of the functionality of these toxins in the lab-
oratory. The progression and role of RBC death in response to attack by bacterial PFTs and its relevance to host-pathogen interactions have been underappreciated. Many PFT-producing pathogens may come into contact with RBCs in the course of colonization or disease, including Gardnerella vaginalis, Streptococcus intermedius, and Streptococcus pneumoniae (9–11). Some of these pathogens can enter the RBC-dominated bloodstream, causing bacteremia, aiding in dissemination and pathogenesis (9, 10, 12, 13). In some cases, bacteremic infections can also lead to acquired (hemolytic) anemia (3). Additionally, G. vaginalis, associated with bacterial vaginosis, proliferates and colonizes to its highest levels at the vaginal mucosa during menses (11). Thus, the interaction of PFT-producing pathogens with mature RBCs has relevance to mechanisms of colonization and disease.

Here, we show that vaginolysin (VLY) and intermedilysin (ILY), hCD59-specific PFTs produced by G. vaginalis and S. intermedius, respectively, induce programmed necrosis (necroptosis) in mature RBCs. Similarly to programmed necrosis in nucleated cells (14), RBC programmed necrosis depends on Fas receptor and Fas ligand (Fas/FasL), RIP1 kinase phosphorylation, and mixed-lineage kinase domain-like (MLKL) protein. RBC programmed necrosis is also associated with assembly of a cytosolic complex called the necosome (14). Also similarly to programmed necrosis in nucleated cells (14), this PCD is antagonized by caspase-8 in mature RBCs. Downstream effector pathways involved in the execution of RBC programmed necrosis included the formation of ceramide by acid sphingomyelinase (aSMase), formation of reactive oxygen species (ROS) by NADPH oxidase (NOX) and iron in the Fenton reaction, and formation of advanced glycation end products (AGEs) via glycosylation. Importantly, we show that RBC programmed necrosis is distinct from apoptosis, the only other known form of PCD in RBCs. Finally, the induction of RBC programmed necrosis enhances the growth of PFT-producing bacteria, suggesting a role for this PCD in the pathogenesis of these organisms.

RESULTS

VLY, an hCD59-specific PFT, causes lipid raft enlargement and recruitment of PCD factors to lipid rafts of mature RBCs. While analyzing the interaction of VLY with lipid rafts of mature human RBCs, we observed an increase in lipid raft-associated proteins (hCD59 and flotillin-1) and lipids (cholesterol, GM1, and GT1b) in detergent-resistant membrane (DRM) fractions derived from lipid rafts (Fig. 1A and B). This indicates an increase in the size/stability of lipid rafts, which occurs during lipid raft-dependent signaling (15, 16). Fas receptor (Fas) and Fas ligand (Fasl), which are hCD59-specific PFTs, caused RBC death that was inhibited by monoclonal antibody (MAb) neutralization of FasL (Fig. 2A and B). The hCD59-independent PFTs pneumolysin (PLY; from Streptococcus pneumoniae) and alpha-toxin (A-tox; from Staphylococcus aureus) did not cause FasL-dependent RBC death (Fig. 2B). VLY, ILY, and PLY are CDCs that may form pores with an external diameter of >15 nm, whereas A-tox is not a CDC and forms pores of 1 to 2 nm in diameter (5, 6). Exogenous recombinant FasL (rFasL) significantly enhanced VLY-mediated RBC death (Fig. 2C), as did an agonistic MAb targeting Fas (Fig. 2D). Notably, low hemolytic doses of all PFTs tested were enhanced when combined with rFasL or agonistic Fas MAb (Fig. 2E and F). We used hCD59 transgenic murine RBCs as a model system, as these are susceptible to VLY and ILY, whereas nontransgenic cells are resistant (Fig. 2G and H). Death of hCD59-transgenic murine RBCs induced by VLY or ILY, but not PLY, was inhibited by FasL neutralization, indicating that FasL-dependent death can be initiated in nonhuman RBCs (Fig. 2H). These results indicate that hCD59-specific PFTs initiate Fas/FasL signaling in RBCs resulting in death and that the combination of Fas/FasL signaling and pore formation primes RBCs for death by any PFT.

hCD59-specific bacterial PFTs induce RIP1-dependent programmed necrosis in mature RBCs. Because hCD59-specific PFTs caused Fas/FasL-dependent RBC death, we hypothesized

![FIG 1](http://mbio.asm.org/figure1.png)

**FIG 1** VLY, an hCD59-specific PFT, induces lipid raft enlargement, including recruitment of Fas and Fasl. (A) RBC detergent-resistant membranes (DRMs) increase in abundance in response to VLY as measured by DPH fluorescence. Cholesterol and proteins increase in DRMs after VLY treatment, with most proteins remaining soluble (SOL). (B) Dot blots showing that raft-associated proteins (CD59 and flotillin-1) and lipids (GM1 and GT1b) increase in DRMs in response to VLY. Hemoglobin (HGB) is excluded from DRMs. (C) Fas and Fasl, normally excluded from rafts, are recruited to DRMs in response to VLY. ***, P < 0.001 (Student’s t test).**
that these PFTs might activate PCD in RBCs. In addition, two components of complexes formed during programmed necrosis (necroptosis) were recruited to RBC lipid rafts in response to VLY. These components, Fas-associated death domain (FADD) and RIP1 kinase (RIP1) are cytosolic and not normally associated with lipid rafts but were found in DRMs following RBC stimulation with VLY (Fig. 3A). This suggested that VLY might activate programmed necrosis, a PCD pathway that occurs in nucleated cell types and can involve induction by Fas/FasL, in mature RBCs (14, 19).

We used necrostatin-1 (nec-1), a small-molecule inhibitor of RIP1 kinase, to explore the induction of Fas/FasL-dependent programmed necrosis in mature RBCs (20). RIP1 phosphorylation and recruitment to the cytosolic necrosome complex are critical for the induction of programmed necrosis (19–21). The importance of RIP1 is such that programmed necrosis is also referred to as RIP1-dependent cell death (14). nec-1 inhibited VLY-induced RBC death over a range of concentrations (Fig. 3B). RIP3 kinase also plays important roles in programmed necrosis (22, 23) by interacting with a downstream protein, mixed-lineage kinase domain-like (MLKL), to exert its effects (24). Inhibition of MLKL with necrosulfonamide (NSA) also reduced RBC death caused by VLY, consistent with a role for programmed necrosis in RBCs (Fig. 3C). Similarly, nec-1 and NSA inhibited RBC death by hCD59-dependent ILY but had no effect on hemolysis by hCD59-independent PLY and A-tox (Fig. 3D to I). These results indicated that hCD59-specific bacterial PFTs, but not hCD59-independent PFTs, induce programmed necrosis in mature RBCs. In addition, rFasL enhanced the hemolysis by all PFTs tested, regardless of intrinsic hCD59 specificity (Fig. 2E). This enhanced death was nec-1 inhibitible, indicating that the combination of Fas/FasL signaling and PFT activity initiates RIP1-dependent programmed necrosis in mature RBCs (Fig. 3J).

hCD59-specific bacterial PFTs induce FasL-dependent RIP1 phosphorylation and necroosome assembly in mature RBCs. To further explore the molecular events associated with programmed
necrosis in RBCs, RIP1 was isolated from RBCs by immunoprecipitation (IP) (Fig. 4A) and probed on immunoblots to determine its phosphorylation state in response to PFTs. RIP1 became phosphorylated (p-RIP1) in RBCs in response to VLY or ILY but not in response to hCD59-independent PFTs (Fig. 4B). RIP1 phosphorylation induced by VLY and ILY was also inhibited by nec-1, confirming the activity of this inhibitor in primary human RBCs (Fig. 4C). The induced p-RIP1 was prevented by FasL neutralization, suggesting that hCD59-specific PFTs induce p-RIP1 through downstream activity of Fas/FasL (Fig. 4D). This seems likely, as addition of rFasL alone to RBCs also resulted induced RIP1 phosphorylation (Fig. 4E). We confirmed the specificity of the IPs for RIP1, as an irrelevant IgG did not precipitate RIP1 (see Fig. S3A in the supplemental material).

Formation of the necrosome is generally associated with programmed necrosis in nucleated cells (25). Necrosomes contain important signaling proteins, RIP1, RIP3, FADD, and caspase-8 (14). To investigate necrosome assembly in RBCs, RIP1 IPs were probed for specific coprecipitants. Necrosome components RIP3 and FADD coprecipitated with RIP1 following stimulation with VLY or ILY, suggesting necrosome assembly. These associations were inhibited by nec-1 (Fig. 4F).

Necrosis-associated caspase-8 antagonizes RBC programmed necrosis. In nucleated cells, caspase-8 is a necrosis component that antagonizes programmed necrosis by cleaving RIP1 and RIP3 (14, 26). To determine if caspase-8 served a similar role in RBCs, we analyzed caspase-8 by IP (Fig. 5A) and found that RIP1 coprecipitated with caspase-8 in RBCs regardless of PFT stimulation, suggesting a constitutive association of these proteins in RBCs but not THP-1 cells (Fig. 5B). Pan-caspase inhibition enhanced RBC death by VLY or ILY (Fig. 5C and D), and this enhanced death was prevented by RIP1 inhibition (Fig. 5E). Specific inhibition of caspase-8, but not caspase-3, enhanced RBC death by VLY or ILY (Fig. 5F), consistent with an antagonistic role for caspase-8 in RBC programmed necrosis similar to its function in programmed necrosis of nucleated cells (14). In agreement with this finding, caspase-8 inhibition led to an increase in RIP1 phosphorylation following VLY stimulation (Fig. 5G). The IPs were specific for caspase-8, as an irrelevant IgG did not pull down caspase-8 (see Fig. S3B in the supplemental material).

NOX/iron-dependent ROS formation and aSMase-dependent ceramide formation are downstream components of RBC programmed necrosis. Cell death by programmed necrosis may involve several different downstream effector pathways, including ceramide formation, ROS formation, phospholipase/calcium activity, and AGE formation by enhanced glycolysis (14). Effector pathways vary by cell type, and several mechanisms may be active within single cell types (14). RBC death induced by VLY and ILY was blunted by inhibition of NOX (Fig. 6A and B), and both VLY and ILY caused an increase in ROS in RBCs (Fig. 6C). Additionally, iron chelation reduced RBC death caused by VLY and ILY and prevented ROS induction by these PFTs (Fig. 6D to F). These results suggest that NOX-dependent ROS contribute to RBC death by programmed necrosis and that ROS formation is enhanced by iron, likely due to the Fenton reaction.

Inhibition of aSMase, which produces ceramide from sphingomyelin, reduced RBC death by VLY and ILY, as did MAb neutralization of ceramide (Fig. 6G to I). VLY and ILY caused significant increases in surface ceramide, whereas hCD59-independent PFTs did not (Fig. 6J). Thus, aSMase-dependent ceramide formation is an additional downstream component in RBC programmed necrosis.
Glycolytic formation of AGEs contributes to the execution of RBC programmed necrosis. AGE formation may occur downstream of programmed necrosis in nucleated cells due to increased glycolysis (27). Exogenous glucose enhanced RBC death by VLY and ILY in a RIP1-dependent manner (Fig. 7A). Glycolysis drove this process, as a nonmetabolizable glucose analog, 2-deoxy-D-glucose, did not affect PFT-mediated RBC death (Fig. 7B). Importantly, glucose uptake had no effect on RBC death by the hCD59-independent PFT, PLY (Fig. 7C). That glycolysis participates in RBC programmed necrosis suggests the involvement of AGEs (27). Indeed, specific inhibition of AGEs reduced RBC death by the hCD59-independent PFT, PLY (Fig. 7D and E). That glycolytic AGE formation plays a crucial role in the demise of RBCs by programmed necrosis.

RBC programmed necrosis is distinct from eryptosis. Although the identification of programmed necrosis in RBCs in response to hCD59-specific PFTs was unexpected, there is a precedent in eryptosis, a PCD unique to RBCs, which was recently described (4). To determine if RBC programmed necrosis was distinct from eryptosis, two well-characterized eryptotic stimuli, hyperosmotic stress and excess calcium, were used (28, 29). Hyperosmotic or calcium-induced eryptosis was not affected by nec-1, did not induce p-RIP1, did not depend on FasL, and was not enhanced by rFasL addition (Fig. 8A to D). Moreover, factors on which eryptosis depends (e.g., intracellular Ca²⁺ and p38 mitogen-activated protein kinase [MAPK] [4, 30]) played no role in RBC programmed necrosis induced by hCD59-specific PFTs (Fig. 8E and F). Thus, programmed necrosis is a new PCD pathway in mature RBCs that is distinct from eryptosis.

Induction of RBC programmed necrosis enhances bacterial growth in vitro. hCD59-specific PFTs induce Fas/FasL-dependent programmed necrosis of mature RBCs while hCD59-independent PFTs do not. This observation raises the question of the potential benefit that RBC programmed necrosis may have for PFT-producing pathogenic bacteria. We hypothesized that induction of programmed necrosis might increase RBC killing at low organism or PFT concentrations, resulting in more efficient release of nutrients that might enhance bacterial growth. To this end, a series of bacterial growth assays were performed during which *G. vaginalis*, *S. intermedius*, and *S. pneumoniae* were cultured with or without human RBCs. Using RIP1 IP and immunoblotting, we confirmed that live *G. vaginalis* and *S. intermedius* induced p-RIP1 (Fig. 9A and B). RIP1 phosphorylation was induced by native VLY or ILY, respectively, as it was prevented by an anti-CDC antibody (31) (Fig. 9A and B; see also Fig. S4 in the}
supplemental material). *G. vaginalis* growth required RBCs, whereas *S. intermedius* growth was significantly enhanced in the presence of RBCs (Fig. 9C and D). Neutralization of RBC FasL reduced *G. vaginalis* and *S. intermedius* growth in the presence of human RBCs (Fig. 9C and D), suggesting that FasL-dependent programmed necrosis of RBCs enhanced the proliferation of *G. vaginalis* and *S. intermedius*. Consistent with the finding that the hCD59-independent PLY did not induce FasL-dependent RBC programmed necrosis, the growth of *S. pneumoniae* (which produces PLY) was unaffected by FasL neutralization in RBCs (Fig. 9E).

Addition of exogenous rFasL allowed all bacterial PFTs to cause RBC programmed necrosis, resulting in enhanced RBC death, regardless of intrinsic hCD59 specificity (Fig. 2E and 3J). Collectively, these results demonstrate that the induction of RBC programmed necrosis enhances bacterial growth. Consistent with the hypothesis that release of RBC cytosolic contents might provide nutrients to prime bacterial growth, addition of purified hemoglobin to cultures also enhanced the growth of all three species tested (see Fig. S5 in the supplemental material).

**FIG 6** RBC programmed necrosis is executed in part by sMase-dependent ceramide formation and NOX/iron-dependent ROS. (A and B) NOX inhibition with 10 μM VAS-2870 reduces RBC death by VLY and ILY compared to vehicle control. (C) VLY and ILY induce ROS in RBCs as measured by DCFDA. (D and E) Iron chelation with 100 μM 2,2-bipyridyl reduces RBC death by VLY or ILY relative to vehicle control. (F) Iron chelation prevents ROS induction by VLY and ILY. (G and H) Inhibition of sMase with 20 μM desipramine (DPA) reduced RBC death by VLY and ILY relative to vehicle control. (I) Ceramide neutralization with MAb 15B4 reduced death by VLY or ILY relative to irrelevant IgM (IgM). (J) VLY and ILY induce surface ceramide as determined by immunofluorescence. ***, *P* < 0.001; ***, *P* < 0.01; *, *P* < 0.05 (two-way analysis of variance, Bonferroni posttest).

**FIG 7** Glycolytic formation of AGEs is a component in the execution of RBC programmed necrosis. (A) Glucose (gluc) uptake by RBCs in a 5 mM solution enhanced death by VLY or ILY and was prevented by nec-1. (B) Uptake of the nonmetabolizable 2-deoxy-d-glucose (2-deoxygluc) had no effect on RBC death. (C) Glucose uptake had no effect on RBC death by the hCD59-independent PLY. (D and E) AGE inhibition with 1 mM pyridoxamine reduced death by VLY or ILY relative to vehicle control. (F) RBC death enhanced by glucose uptake is prevented by AGE inhibition. (G) VLY and ILY induce RBC AGE formation as determined by whole-cell immunofluorescence assay. ***, *P* < 0.001; ***, *P* < 0.01; *, *P* < 0.05 (two-way analysis of variance, Bonferroni posttest).
RBC programmed necrosis and eryptosis are distinct. The discovery of programmed necrosis in RBCs by hCD59-specific PFTs is not the first instance of RBC PCD. Eryptosis is a Ca\(^{2+}\)-, p38 MAPK-dependent PCD process in RBCs (4). It is characterized by phosphatidylserine externalization and ceramide formation, marking these RBCs for macrophage ingestion (4, 18). Our results demonstrate that RBC programmed necrosis differs from eryptosis, functioning as an independent, previously unrecognized PCD pathway in mature RBCs. It is possible that eryptosis contributes to “natural” RBC death/removal due to noninfectious injury, whereas programmed necrosis is induced by infection with PFT-producing pathogens.

Significance of RBC programmed necrosis. hCD59-specific PFT induction of RBC programmed necrosis is significant for at least two reasons: (i) it provides new understanding of the relevance of programmed necrosis to RBC biology and physiology and (ii) it suggests that RBC programmed necrosis may play a role in colonization or pathogenesis of hCD59-specific PFT-producing pathogens. Whereas eryptosis is important, it does not share key molecular features of PCD that occur in nucleated cells, including caspase dependence (whereas senescent and storage-damaged RBCs display active caspasess [35, 36], these critical apoptotic enzymes have not been conclusively linked to eryptosis [28, 37, 38]) and the requirement of extrinsic ligands of the TNF superfamily (37). Therefore, eryptosis is a PCD unique to mature RBCs that is not shared with nucleated cells. Conversely, RBC programmed necrosis proceeds in a manner molecularly similar to nucleated cell necroptosis, sharing many key features. These include dependence on RIP1 phosphorylation, MLKL, and extrinsic ligands of the TNF superfamily (e.g., Fasl); antagonism by caspase-8; and necrosome assembly. Moreover, whereas Fas and Fasl differ in their cellular localizations during oxidative stress and in senescent RBCs (18), they were reported to be nonfunctional in mature RBCs (37, 39). Nonetheless, we show that Fas and Fasl drive programmed necrosis in mature RBCs, promoting RIP1 phosphorylation. The intimate involvement of Fasl/Fasl in RBC programmed necrosis may explain the differential localization of Fas/Fasl previously seen in senescent RBCs (18), suggesting that aged RBCs may be primed for programmed necrosis. These findings expand our knowledge of RBC physiology by identifying other PCD pathways in RBCs. Given the similarities of programmed necrosis in RBCs and nucleated cells, we speculate that caspase-dependent apoptosis, resembling that of nucleated cells, may occur in mature RBCs. Alternatively, it is possible that mature RBCs have lost the capacity for classical apoptosis but retained the capacity for programmed necrosis.

As RBC programmed necrosis enhanced bacterial proliferation in vitro, this PCD may play a role in bacterial growth and pathogenesis in vivo. G. vaginalis colonizes the lower genital tract of women (11). The growth/presence of G. vaginalis varies throughout the menstrual cycle, with the highest levels of G. vaginalis occurring during menses (11). This suggests that RBC availability may affect bacterial growth. We speculate that VLY-mediated RBC programmed necrosis plays a significant role in the pathogenesis of bacterial vaginosis. In addition, S. intermedius infection is associated with abscess formation in the brain and liver, resulting from hematogenous spread from mucosal surfaces (10). As RBC programmed necrosis enhances S. intermedius growth in vitro, we speculate that this PCD may aid its dissemination and growth. The potential for increased bacterial growth during the
hematogenous phase of *S. intermedius* infections as a result of RBC programmed necrosis could lead to exacerbated abscess formation due to greater bacterial burden. When considering this growth benefit, the direct induction of hCD59-specific RBC programmed necrosis by VLY and ILY might explain a potential selective advantage associated with human-specific PFT production by *G. vaginalis* and *S. intermedius*.

Pneumonia due to *S. pneumoniae* may progress to bacteremia (9), but as PLY cannot induce RBC programmed necrosis, a role for this PCD in pneumococcal infection is unclear. Nonetheless, pneumococcal infection is associated with FasL release, because *S. pneumoniae* elicits increased FasL levels in lung (40) and causes FasL-dependent bystander death following phagocytosis (41). As shown here, PLY can induce RBC programmed necrosis when combined with rFasL, raising the possibility that this PCD plays a role in systemic pneumococcal infection. These potential roles of RBC programmed necrosis in promoting the pathogenesis of different microbes are intriguing and suggest the possibility for therapeutic intervention by targeting factors specific to this PCD.

**MATERIALS AND METHODS**

**Human cells.** Primary human RBCs, with or without leukoreduction using Purecell Neo leukocyte reduction filters (Haemonetics), were obtained from healthy volunteers under a protocol approved by the Columbia University Institutional Review Board. Leukoreduction did not affect results. Murine RBCs were obtained from wild-type or hCD59 transgenic C57BL/6j mice (42), which were used in accordance with a protocol approved by the Columbia University Institutional Animal Care and Use Committee. THP-1 cells (ATCC TIB-202) were grown in RPMI 1640 plus GlutaMAX plus 25 mM HEPES (Invitrogen) supplemented with 10% fetal bovine serum and 10 μg/ml ciprofloxacin.

**DRM isolation.** Human RBC suspensions (20%), treated with or without 1 μg/ml VLY at 37°C for 0.5 h, were solubilized in 1% Triton X-100 at 4°C for 1 h. DRMs were isolated as described previously (43).

**Hemolysis assays.** Hemolysis assays were done in Dulbecco’s phosphate-buffered saline (DPBS) (7). Recombinant PFTs were expressed and purified as previously described (7, 44, 45) and used at 1 HU unless specified otherwise. For pharmacological or Ab inhibition, RBCs were pretreated with inhibitors for 1 h at 37°C. rFasL or MAb 2R2 (Enzo Life Sciences) was added with PFTs. None of the inhibitors tested affected RBC binding by a green fluorescent protein (GFP) fusion protein of the VLY binding domain (see Fig. S6 in the supplemental material). Eryptosis was induced with 950 mM sucrose or 1 mM CaCl2 at 37°C for 18 h. For glucose uptake, RBCs were incubated with 5 mM glucose for 18 h, and glucose was removed by centrifugation.

**Immunoprecipitation.** Human RBC suspensions (20%) in DPBS were treated with PFTs (0.5 HU), rFasL (1 μg/ml), or bacteria (*G. vaginalis* or *S. intermedius* at an optical density at 600 nm [OD600] of 0.6) for 30 min at 37°C and sonicated, and phosphatase inhibitor cocktail set III (1:100; Millipore) was added. THP-1 cells were adjusted to a concentration of 5 × 10^7 cells/ml and sonicated. Sonicates from either cell type were precleared with 200 μl of control agarose resin (Pierce); 10 μg of anti-RIP1 MAb G322-2 (BD) or anti-caspase-8 MAb 12F5 (AG Scientific) was added and incubated overnight at 4°C. Protein G plus agarose (100 μl; Pierce) was
added for 2 h at room temperature. Precipitates were suspended in 50 μl 1× NuPAGE LDS sample buffer and boiled.

**Anti-CDC antibody.** The anti-CDC polyclonal antibody was raised against VLY in rabbits and was described previously (31). This antibody cross-reacts with other CDCs as shown in Fig. S4 in the supplemental material.

**Fluorescence assays.** Human RBC suspensions (0.5%) were incubated with sublytic doses (<0.2 HU) of PFTs at 37°C for 1 h. To detect ROS, 2,7-dichlorofluorescein diacetate (20 μM; DCFDA; Invitrogen) was added. To detect ceramide or AGEs, RBCs were labeled with 10 μg/ml of 15B4 anti-ceramide MAb or anti-AGE polyclonal antibody (PAb) (Ab-Cam) for 1 h and anti-mouse IgM or IgG fluorescein isothiocyanate (FITC) conjugates for 1 h at 37°C and washed. To measure DRMs, diphenylhexatriene (DPhH; Invitrogen) was added to samples at 2 μg/ml. Fluorescence was measured using an Infinite M200 (Tecan) at excitation/emission wavelengths of 495 nm/525 nm for DCFDA, 490 nm/525 nm for FITC, and 360 nm/430 nm for DPhH. Cholesterol was measured using the Amplex red cholesterol assay kit (Invitrogen).

**Immunobots.** For dot/Western blot assays, the following Abs were used: anti-RIP1 (BD; G32-22), anti-RIP3 (Thermo Scientific), anti-FADD (Millipore), anti-caspase-8 (AG Scientific), anti-CD59 (Thermo Scientific), anti-FasL (Thermo Scientific), and anti-Fas (Thermo Scientific). For p-RIP1, anti-hemoglobin (Santa Cruz) at dilutions of 1:1,000. For p-RIP3, anti-phospho-Ser/Thr (Cell Signaling Technology) was used at 1:500.

**Bacterial growth assays.** G. vaginalis strain ATCC 49145 was inoculated in brain heart infusion (BHI) broth with 10% fetal bovine serum at 37°C and 5% CO2 with or without 5% human RBCs and grown for 18 h. *S. intermedia* strain ATCC 27335 and *S. pneumoniae* strain R6 were inoculated in Trypticase soy (TS) broth at 37°C with or without 5% human RBCs and grown for 5 h. For fastL inhibition, 5 μg/ml of NOK-1 or an irrelevant mouse IgG was added to the medium 1 h before inoculation. For fastL experiments, 1 μg/ml was added with inocula. Growth was assessed by quantitative culture.

**Statistics.** Data are presented as means ± standard deviations (SD) from 3 experiments analyzed by the indicated statistical tests (GraphPad Prism).

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl?doi=10.1128/mBio.01251-14/-/DCSupplemental.

**REFERENCES**

1. Hod EA, Arinsburg SA, Francis RO, Hendrickson JE, Zimring JC, Spitalnik SL. 2010. Use of mouse models to study the mechanisms and consequences of RBC clearance. Vox Sang. 99:99–111. http://dx.doi.org/10.1111/j.1430-4887.2010.01327.x.

2. Alaarg A, Schifflers RM, van Solinge WW, van Wijk R. 2011. Mapping the intermedilysin-phage receptor interface reveals a deep correspondence with the Fn3 domain of reovirus M1 protein. J. Biol. Chem. 286:20952–20962. http://dx.doi.org/10.1074/jbc.M111.337446.

3. Schwabke JR, Muzny CA, Josey WE. 2014. Role of Gardnerella vaginalis in the pathogenesis of bacterial vaginosis—a conceptual model. J. Infect. Dis. 210:338–343. http://dx.doi.org/10.1093/infdis/jiu089.

4. Johnson AP, Boustouller YL. 1987. Extra-vaginal infection caused by Gardnerella vaginalis. Epidemiol. Infect. 98:131–137. http://dx.doi.org/10.1017/S095026880001835.

5. Lagacé-Wiens PR, Ng B, Reimer A, Burdz T, Wiebe D, Bernard K. 2008. Functional and phylogenetic characterization of vaginolysin, the human-specific cytolytic protein of *Gardnerella vaginalis*. J. Bacteriol. 190:3896–3903. http://dx.doi.org/10.1128/JB.01965-07.

6. Wickham SE, Hotze EM, Farrand AJ, Polekhina G, Nero TL, Tomlinson S, Parker MW, Tweten RK. 2011. Mapping the intermedilysin-human CD99 receptor interface reveals a deep correspondence with the Fn3 domain of reovirus M1 protein. J. Biol. Chem. 286:20952–20962. http://dx.doi.org/10.1074/jbc.M111.337446.

7. Gillespie SH, Balakrishnan I. 2000. Pathogenesis of pneumococcal infection. J. Med. Microbiol. 49:1057–1067.

8. Tran MP, Caldwell-McMillan M, Khaledi W, Young VB. 2008. Streptococcus intermedus causes infective endocarditis and abscesses: a report of three cases and review of the literature. BMC Infect. Dis. 8:154; http://dx.doi.org/10.1186/1471-2334-8-154.

9. Wickham SE, Hotze EM, Farrand AJ, Polekhina G, Nero TL, Tomlinson S, Parker MW, Tweten RK. 2011. Mapping the intermedilysin-human CD99 receptor interface reveals a deep correspondence with the Fn3 domain of reovirus M1 protein. J. Biol. Chem. 286:20952–20962. http://dx.doi.org/10.1074/jbc.M111.337446.

10. Wickham SE, Hotze EM, Farrand AJ, Polekhina G, Nero TL, Tomlinson S, Parker MW, Tweten RK. 2011. Mapping the intermedilysin-human CD99 receptor interface reveals a deep correspondence with the Fn3 domain of reovirus M1 protein. J. Biol. Chem. 286:20952–20962. http://dx.doi.org/10.1074/jbc.M111.337446.

11. Wickham SE, Hotze EM, Farrand AJ, Polekhina G, Nero TL, Tomlinson S, Parker MW, Tweten RK. 2011. Mapping the intermedilysin-human CD99 receptor interface reveals a deep correspondence with the Fn3 domain of reovirus M1 protein. J. Biol. Chem. 286:20952–20962. http://dx.doi.org/10.1074/jbc.M111.337446.

12. Wickham SE, Hotze EM, Farrand AJ, Polekhina G, Nero TL, Tomlinson S, Parker MW, Tweten RK. 2011. Mapping the intermedilysin-human CD99 receptor interface reveals a deep correspondence with the Fn3 domain of reovirus M1 protein. J. Biol. Chem. 286:20952–20962. http://dx.doi.org/10.1074/jbc.M111.337446.

13. Wickham SE, Hotze EM, Farrand AJ, Polekhina G, Nero TL, Tomlinson S, Parker MW, Tweten RK. 2011. Mapping the intermedilysin-human CD99 receptor interface reveals a deep correspondence with the Fn3 domain of reovirus M1 protein. J. Biol. Chem. 286:20952–20962. http://dx.doi.org/10.1074/jbc.M111.337446.

14. Wickham SE, Hotze EM, Farrand AJ, Polekhina G, Nero TL, Tomlinson S, Parker MW, Tweten RK. 2011. Mapping the intermedilysin-human CD99 receptor interface reveals a deep correspondence with the Fn3 domain of reovirus M1 protein. J. Biol. Chem. 286:20952–20962. http://dx.doi.org/10.1074/jbc.M111.337446.

15. Wickham SE, Hotze EM, Farrand AJ, Polekhina G, Nero TL, Tomlinson S, Parker MW, Tweten RK. 2011. Mapping the intermedilysin-human CD99 receptor interface reveals a deep correspondence with the Fn3 domain of reovirus M1 protein. J. Biol. Chem. 286:20952–20962. http://dx.doi.org/10.1074/jbc.M111.337446.
capacities increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 187:1477–1485. http://dx.doi.org/10.1084/jem.187.9.1477.

27. Van Herreweghe F, Mao J, Chaplen FW, Grooten J, Gevaert K, Vandekerckhove J, Vancompernolle K. 2002. Tumor necrosis factor-induced modulation of glyoxalase 1 activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE. Proc. Natl. Acad. Sci. U. S. A. 99:949–954. http://dx.doi.org/10.1073/pnas.012432399.

28. Bratosin D, Estaquier J, Petit F, Arnault D, Quatannens B, Tissier JP, Van Herreweghe F, Mao J, Chaplen FW, Grooten J, Gevaert K, Vandekerckhove J, Vancompernolle K. 2002. Tumor necrosis factor-induced modulation of glyoxalase 1 activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE. Proc. Natl. Acad. Sci. U. S. A. 99:949–954. http://dx.doi.org/10.1073/pnas.012432399.

29. Lang F, Lang KS, Wieder T, Myssina S, Birka C, Lang PA, Kaiser S, Kempe D, Duranton C, Huber SM. 2003. Cation channels, cell volume and the death of an erythrocyte. Pflugers Arch. 447:121–125. http://dx.doi.org/10.1007/s00424-003-1150-8.

30. Gatidis S, Zelenak C, Fajol A, Lang E, Jilani K, Michael D, Qadri SM, Strasser A, Jost PJ, Nagata S. 2000. The central role of Fas-ligand signaling in the immune system. Immunity 10:10.1016/s1074-1611(00)80066-8.

31. Randis TM, Kulkarni R, Aguilar JL, Ratner AJ. 2009. Antibody-based detection and inhibition of vaginolysin, the cytolytic toxin of the prokaryote Borrelia burgdorferi have the same properties as eukaryotic pore-forming toxins. J. Biol. Chem. 284:12994–12998. http://dx.doi.org/10.1074/jbc.M109.804150.

32. Rampersaud R, Planet PJ, Randis TM, Kulkarni R, Aguilar JL, Lehrer RI, Ratner AJ. 2011. Inerolysin, a cholesterol-dependent cytolysin produced by Lactobacillus iners. J. Bacteriol. 193:1034–1041. http://dx.doi.org/10.1128/JB.00694-10.